A detailed history of American Portfolios Advisors transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, American Portfolios Advisors holds 56 shares of BLUE stock, worth $17. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56
Holding current value
$17
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023

BUY
$3.75 - $7.39 $210 - $413
56 New
56 $354,000
Q2 2021

Mar 22, 2023

BUY
$18.04 - $22.09 $1,804 - $2,209
100 Added 178.57%
156 $4.99 Million
Q1 2021

Mar 22, 2023

BUY
$16.59 - $33.89 $1,659 - $3,389
100 Added 178.57%
156 $4.7 Million
Q4 2020

Mar 22, 2023

BUY
$27.5 - $37.92 $20,625 - $28,440
750 Added 1339.29%
806 $34.9 Million
Q3 2020

Mar 22, 2023

BUY
$34.44 - $43.75 $48,353 - $61,425
1,404 Added 2507.14%
1,460 $78.8 Million
Q2 2020

Mar 24, 2023

BUY
$27.12 - $45.97 $9,492 - $16,089
350 Added 30.97%
1,480 $90.3 Million
Q1 2020

Mar 24, 2023

BUY
$26.16 - $63.5 $28,095 - $68,199
1,074 Added 1917.86%
1,130 $51.9 Million
Q4 2019

Mar 24, 2023

BUY
$46.96 - $61.67 $38,695 - $50,816
824 Added 1471.43%
880 $77.2 Million
Q2 2019

Mar 24, 2023

BUY
$75.84 - $105.21 $303 - $420
4 Added 7.14%
60 $7.63 Million
Q4 2018

Mar 24, 2023

SELL
$59.1 - $93.26 $8,096 - $12,776
-137 Reduced 69.54%
60 $5.95 Million
Q3 2018

Mar 24, 2023

BUY
$88.86 - $117.49 $12,529 - $16,566
141 Added 251.79%
197 $28.8 Million
Q2 2018

Mar 24, 2023

BUY
$99.64 - $127.59 $6,675 - $8,548
67 Added 63.81%
172 $27 Million
Q1 2018

Mar 24, 2023

BUY
$105.8 - $150.94 $5,184 - $7,396
49 Added 87.5%
105 $17.9 Million

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $24.7M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.